Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | SHBG | P04278 | 1/20 | 0.69 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | GABRP | O00591 | 2/20 | 0.61 |
| ▸ | GABRD | O14764 | 2/20 | 0.61 |
| ▸ | G6PD | P11413 | 2/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7376650 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL19750469 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL25854513 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6816494 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL8499073 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL15426615 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6812905 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL15959419 | 0.86 | LMNA (0.52) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL15837753 | 0.86 | LMNA (0.52) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL15959577 | 0.86 | LMNA (0.52) | LMNAGPBAR1CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190770-A1 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | WASHINGTON UNIVERSITY | 2023-06-22 | — | — | US | disclosed |
| US-20170232006-A1 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | WASHINGTON UNIVERSITY | 2017-08-17 | — | — | US | disclosed |
| US-20170190732-A1 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | WASHINGTON UNIVERSITY | 2017-07-06 | — | — | US | disclosed |
| US-9676812-B2 | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | WASHINGTON UNIVERSITY (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170152282-A9 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | WASHINGTON UNIVERSITY (US) | 2017-06-01 | — | — | US | disclosed |
| US-9630986-B2 | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | WASHINGTON UNIVERSITY (US) | 2017-04-25 | — | — | US | disclosed |
| US-20150315230-A1 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | WASHINGTON UNIVERSITY (US) | 2015-11-05 | — | — | US | disclosed |
| US-20140235600-A1 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | WASHINGTON UNIVERSITY (US) | 2014-08-21 | — | — | US | disclosed |
| EP-0837874-B1 | NEUROACTIVE STEROIDS OF THE ANDROSTANE AND PREGNANE SERIES | EURO CELTIQUE SA (LU) | 2004-12-15 | — | — | EP | disclosed |
| US-6780853-B1 | FOR MODULATING BRAIN EXCITABILITY | EURO-CELTIQUE S.A. (LU) | 2004-08-24 | — | — | US | disclosed |
| EP-1288220-A2 | Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series | Purdue Pharma Ltd. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-5925630-A | MODULATION OF BRAIN EXCITABILITY TO RELIEVE STRESS, ANXIETY, INSOMNIA AND MOOD DISORDERS | COCENSYS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0837874-A2 | NEUROACTIVE STEROIDS OF THE ANDROSTANE AND PREGNANE SERIES | Cocensys, Inc. (US) | 1998-04-29 | — | — | EP | disclosed |
| WO-1996040043-A2 | NEUROACTIVE STEROIDS OF THE ANDROSTANE AND PREGNANE SERIES | COCENSYS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-4297350-A | ORAL ANTIFERTILITY AGENTS; REVERSIBLE | THE UPJOHN COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235600-A1 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | GABBR1, CYP21A2, SLC18A2 | LMNA 3809/4885GPBAR1 462/4885CYP3A4 193/4885 |
| US-20170190732-A1 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | GABBR1, CYP21A2, SLC18A2 | LMNA 3809/4885GPBAR1 462/4885CYP3A4 193/4885 |
| US-20170232006-A1 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | GABBR1, CYP21A2, SLC18A2 | LMNA 3809/4885GPBAR1 462/4885CYP3A4 193/4885 |
| US-20230190770-A1 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | GABBR1, CYP21A2, SLC18A2 | LMNA 3809/4885GPBAR1 462/4885CYP3A4 193/4885 |
| US-20170152282-A9 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | GABBR1, CYP21A2, SLC18A2 | LMNA 3809/4885GPBAR1 462/4885CYP3A4 193/4885 |
| US-20150315230-A1 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME | GABBR1, CYP21A2, SLC18A2 | LMNA 3809/4885GPBAR1 462/4885CYP3A4 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.